1
|
Kinsey C, Camolotto S, Boespflug A, Gullien K, Truong A, Foth M, Shea J, Seipp M, Yap J, Burrell L, Lum D, Whisenant J, Cavalier C, Rehbein K, Cutler S, Afotler K, Welm A, Welm B, Scaife C, Snyder E, McMahon M. Abstract IA25: Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers. Cancer Res 2020. [DOI: 10.1158/1538-7445.mel2019-ia25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Although the RAF>MEK>ERK MAP kinase pathway is key to the development of many RAS-mutated cancers, efforts to target this pathway with pharmacologic inhibitors have failed to deliver clinical benefit to patients. Here we show that inhibition of RAS>RAF>MEK>ERK signaling in RAS-mutated cancer cell lines elicits autophagy, a process of cellular recycling that protects cancer cells from the potentially cytotoxic effects of RAF>MEK>ERK pathway inhibition. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic antiproliferative effects against cell lines in vitro and promotes regression of xenografted patient-derived tumors in mice. Finally, treatment of a cancer patient with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking, disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven malignancies such as melanoma, lung, and pancreatic cancer.
Citation Format: Conan Kinsey, Soledad Camolotto, Amelie Boespflug, Katrin Gullien, Amanda Truong, Mona Foth, Jill Shea, Michael Seipp, Jeffrey Yap, Lance Burrell, David Lum, Jonathan Whisenant, Courtney Cavalier, Kaitren Rehbein, Stephanie Cutler, Kajsa Afotler, Alana Welm, Bryan Welm, Courtney Scaife, Eric Snyder, Martin McMahon. Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA25.
Collapse
Affiliation(s)
- Conan Kinsey
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | - Amelie Boespflug
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Katrin Gullien
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Amanda Truong
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Mona Foth
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Jill Shea
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Michael Seipp
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Jeffrey Yap
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Lance Burrell
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - David Lum
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | | | - Kaitren Rehbein
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Stephanie Cutler
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Kajsa Afotler
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Alana Welm
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Bryan Welm
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Courtney Scaife
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Eric Snyder
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Martin McMahon
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| |
Collapse
|
4
|
van Rossum BJ, Castellani F, Rehbein K, Pauli J, Oschkinat H. Assignment of the nonexchanging protons of the alpha-spectrin SH3 domain by two- and three-dimensional 1H-13C solid-state magic-angle spinning NMR and comparison of solution and solid-state proton chemical shifts. Chembiochem 2001; 2:906-14. [PMID: 11948879 DOI: 10.1002/1439-7633(20011203)2:12<906::aid-cbic906>3.0.co;2-m] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The assignment of nonexchanging protons of a small microcrystalline protein, the alpha-spectrin SH3 domain (7.2 kDa, 62 residues), was achieved by means of three-dimensional (3D) heteronuclear (1H-13C-13C) magic-angle spinning (MAS) NMR dipolar correlation spectroscopy. With the favorable combination of a high B(0)-field, a moderately high spinning frequency, and frequency-switched Lee-Goldburg irradiation applied during 1H evolution, a proton linewidth < or =0.5 ppm at 17.6 Tesla was achieved for the particular protein preparation used. A comparison of the solid-state 1H chemical shifts with the shifts found in solution shows a remarkable similarity, which reflects the identical protein structures in solution and in the solid. Significant differences between the MAS solid- and liquid-state 1H chemical shifts are only observed for residues that are located at the surface of the protein and that exhibit contacts between different SH3 molecules. In two cases, aromatic residues of neighboring SH3 molecules induce pronounced upfield ring-current shifts for protons in the contact area.
Collapse
Affiliation(s)
- B J van Rossum
- Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Strasse 10, 13125 Berlin, Germany.
| | | | | | | | | |
Collapse
|